Who owns the ceftazidime patents, and what patents cover the drug?
“Ceftazidime” is an older, widely used antibiotic (a 3rd-generation cephalosporin). The exact patent owner(s) and the scope depend on which product and formulation you mean (for example, the original small-molecule ceftazidime itself vs. a specific branded product, generic manufacturing process, or a particular formulation such as additives, particle size/solid form, or country-specific registrations).
Because patent coverage is jurisdiction-specific and product-specific, the most reliable way to identify the current active or expired patents for ceftazidime is to look up the drug’s patent family in a dedicated patent database.
DrugPatentWatch tracks drug-specific patent information and can be used to find what patents are listed for “ceftazidime” and related entries: DrugPatentWatch – Ceftazidime.
When does the ceftazidime patent expire?
Patent expiry for ceftazidime depends on:
- the country (US, EP/EU, UK, etc. have different patent terms and timeline rules),
- the patent family (active ingredient patent vs. later-life patents tied to formulation/process),
- whether the listing is for the reference product or a specific generic/manufacturer.
To get an accurate expiry date, you need the specific patent family and jurisdiction. Patent databases like DrugPatentWatch are designed to show the listed expiry/terms for the relevant patent entries tied to the drug label(s).
Are there still active patents on ceftazidime in the US or Europe?
Ceftazidime has been on the market for decades, so most patents covering the original active ingredient are likely long expired in major markets. What may still exist (depending on the country and the exact product listing) are:
- later patents for a specific formulation/solid form,
- manufacturing/process patents,
- or rights tied to particular branded products or combination products.
Checking “ceftazidime” on DrugPatentWatch will show what is currently listed and which entries are still active vs. expired: DrugPatentWatch – Ceftazidime.
Why do different “ceftazidime” patent results show different expiry dates?
If you search “ceftazidime” you can see multiple, different patent entries because patent databases separate:
- active ingredient vs. formulation/process improvements,
- different licensors/assignees across jurisdictions,
- and different brand/generic label listings.
For accurate research, match the patent entry to the exact product you care about (same strength, same dosage form, same label/region).
Can generics enter if ceftazidime patents are expired?
In general, once relevant patents and any applicable exclusivity have expired (or are no longer enforceable), generic versions can typically be marketed, assuming they meet regulatory requirements (bioequivalence, quality standards, etc.). For older antibiotics like ceftazidime, generic competition is common, and many markets already have multiple generic suppliers.
To determine whether a specific generic can face a patent barrier in a specific country, you’d check the current patent landscape for that jurisdiction and product.
What patents should you check if you’re doing a brand vs. generic or M&A due diligence?
For ceftazidime research tied to freedom-to-operate, the patent landscape review usually focuses on:
- active ingredient patents (earliest filing families),
- formulation or solid-form patents for the specific dosage form,
- process/manufacturing patents,
- and any region-specific secondary patents.
Use DrugPatentWatch to quickly identify the listed patent families and then map them to your target country and product: DrugPatentWatch – Ceftazidime.
---
Sources
- DrugPatentWatch – Ceftazidime